# Tandem Diabetes Care, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Tandem Diabetes Care, Inc). ## Overview Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy. Its portfolio includes insulin pumps, mobile applications, and related software and supplies sold in the United States and in international markets through a mix of direct operations and distributors. ## Products & services • t:slim X2 insulin pump • Tandem Mobi insulin pump • Control-IQ+ automated insulin delivery • Infusion sets and insulin cartridges • Diabetes management apps and insights - **Insulin pumps** (45%) — Reusable insulin pump hardware used for intensive insulin therapy. - **Consumables and supplies** (40%) — Cartridges, infusion sets, and other recurring pump-related supplies. - **Automated insulin delivery software** (10%) — Algorithms and software features such as Control-IQ+ that automate dosing. - **Digital diabetes applications and insights** (5%) — Connected software tools that support monitoring, training, and data review. - t:slim X2 insulin pump - Tandem Mobi insulin pump - Control-IQ+ automated insulin delivery - Infusion sets and insulin cartridges - Diabetes management apps and insights ## Customers Tandem sells primarily to people living with insulin-dependent diabetes, especially individuals with type 1 diabetes who need intensive insulin therapy. The company also serves a smaller and expanding group of adults with type 2 diabetes who require intensive insulin treatment, along with the healthcare providers and diabetes educators who help initiate and train users on the devices. - **Type 1 diabetes patients** (primary) — Primary users of Tandem pumps and AID systems; they buy for intensive insulin management and convenience. - **Type 2 diabetes patients requiring intensive insulin therapy** (secondary) — Adults eligible for pump therapy in selected markets; they buy for tighter glucose control and simpler dosing. - **Healthcare providers and diabetes clinics** (primary) — Prescribe devices, support onboarding, and influence product selection based on clinical outcomes. - **Third-party payors and reimbursement systems** (primary) — Influence access through medical and pharmacy benefit coverage and reimbursement terms. - People with type 1 diabetes using intensive insulin therapy - Adults with type 2 diabetes requiring intensive insulin therapy - Healthcare providers who prescribe and support pump therapy - Diabetes educators who train patients on device use - Third-party payors and reimbursement channels that enable access ## Geography Tandem is headquartered in the United States and sells in more than 25 countries worldwide. The U.S. and Canada are served through direct sales and support, while many international markets have historically relied on distributors; the company has also begun expanding direct operations in selected European markets. - United States is the core market and main commercial base - Canada is served alongside the U.S. through direct teams - International sales span more than 25 countries - Many non-U.S. markets have historically used distributors - Direct operations are being expanded in selected European markets ## Strategy Tandem’s strategy centers on expanding access to its insulin delivery systems through a broader reimbursement footprint, including both medical and pharmacy benefit channels. It is also extending its product platform with smaller form factors, extended-wear options, and more advanced automation to improve usability and strengthen its position in automated insulin delivery. - **Broaden reimbursement access** (short-term) — Coverage and benefit design directly affect patient adoption and recurring supply sales. - **Expand the product platform** (medium-term) — New form factors and software features help differentiate the offering and support retention. - **Increase international direct presence** (medium-term) — Direct operations can improve customer support, reimbursement control, and market execution. - **Advance automation and closed-loop capabilities** (long-term) — More automated insulin delivery can improve clinical outcomes and strengthen product relevance. - Expand reimbursement through medical and pharmacy benefit channels - Grow the installed base and retain users over time - Broaden the addressable market beyond type 1 diabetes - Advance Mobi and t:slim X2 with new pump and infusion options - Move toward more automated and eventually fully closed-loop therapy ## Risks Tandem depends heavily on reimbursement access, distributor execution, and continued adoption of insulin pump therapy, so any disruption in coverage or channel performance can affect sales. The business also faces product, regulatory, supply chain, and competitive risks typical of medical device companies, including the possibility that new diabetes technologies or safety concerns reduce demand for its systems. - **Reimbursement and coverage risk** [high] — Pump adoption depends on third-party payor coverage and benefit design, especially in the U.S. - **Distributor dependence** [high] — A small number of independent distributors fulfill orders in key markets and may also sell competing products. - **Competitive and technology obsolescence** [medium] — Alternative pumps, CGM-linked systems, or new diabetes therapies could reduce the appeal of Tandem's devices. - **Supplier concentration and manufacturing disruption** [high] — The company relies on third-party suppliers for components and products, creating supply continuity risk. - **Regulatory and clinical execution risk** [medium] — Clearances, trials, and human factors studies are required before commercialization of new products. - Reimbursement changes can reduce access and slow adoption - Distributor dependence can limit U.S. and international execution - Competition and new diabetes technologies can pressure demand - Supplier concentration can disrupt component availability - Regulatory and clinical trial delays can slow product launches ## Accounting Revenue recognition is closely tied to the mix of durable pump hardware and recurring consumables, with reimbursement timing affecting when sales are recorded. Investors should also watch estimates for warranty reserves, inventory and supply commitments, and any impairment or valuation judgments tied to acquisitions, technology assets, and debt-related financing costs. - **Revenue recognition for pumps and supplies** — Quarterly comparability and mix between hardware and consumables - **Warranty reserve estimates** — Cost of sales and accrued liabilities - **Inventory and purchase commitments** — Gross margin and inventory valuation - **Acquisition-related intangible assets** — Operating expenses and balance sheet carrying values - **Debt and convertible note accounting** — Interest expense, dilution, and liquidity presentation - Pump hardware and recurring supplies may be recognized differently - Reimbursement timing can shift quarterly revenue patterns - Warranty reserves depend on product performance estimates - Inventory and supplier commitments can affect provisions - Acquisition-related intangibles and financing costs require judgment --- *Last updated: 2026-04-29T05:01:20.207242+00:00*